Roumen Nakov - Concepedia

Author

Roumen Nakov

Hexal (Germany)

Also Known As

Frank Misselwitz, R NAKOV, R Nakov, R. Nakov, Roumen L. Nakov, Roumen Nakov

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Hexal (Germany)Duke Medical Center Ludwig-Maximilians-Universität München Jones Institute PRA Health Sciences

About

Roumen Nakov is an author at Hexal (Germany) specializing in medicine, physiology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	47
2	Pharmacology	3	3	47
3	Social Sciences	2	2	31
4	Neuroscience	2	2	31
5	Anesthesia	1	1	18

Roumen Nakov

Publications

Citations

H-Index

Page 1

	Year	Citations
Use of the Low-Molecular-Weight Heparin Reviparin to Prevent Deep-Vein Thrombosis after Leg Injury Requiring Immobilization Michael R. Lassen, Lars C. Borris, Roumen Nakov New England Journal of Medicine	2002	201
Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis H.K. Breddin, V. Hach-Wunderle, Roumen Nakov, New England Journal of Medicine	2001	193
Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension Roumen Nakov, Egon Pfarr, Siegfried Eberle, American Journal of Hypertension	2002	172
Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparin Edelgard Lindhoff‐Last, Roumen Nakov, Frank Misselwitz, British Journal of Haematology	2002	130
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy Kimberly Blackwell, Vladimir Semiglazov, Dmitriy Krasnozhon, Annals of Oncology	2015	81
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis Vijay V. Kakkar, Debra Hoppenstead, Jawed Fareed, Blood	2002	43
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial Kimberly Blackwell, Roman Donskih, C. Michael Jones, The Oncologist	2016	40
Randomized, Double-Blind Study Comparing Proposed Biosimilar La-Ep2006 with Reference Pegfilgrastim in Breast Cancer Nadia Harbeck, Oleg Lipatov, Dmitry Udovitsa, Future Oncology	2016	37
Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure Veselin Mitrović, Petar Seferović, Slobodan Dodić, Circulation Heart Failure	2009	32
Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects Roumen Nakov, Sreekanth Gattu, Jessie Wang, British Journal of Clinical Pharmacology	2018	20

Page 1